The estimated Net Worth of Phil Skolnick is at least $1.45 Million dollars as of 27 January 2023. Dr Skolnick owns over 480 units of Opiant Pharmaceuticals Inc stock worth over $444,966 and over the last 6 years he sold OPNT stock worth over $316,160. In addition, he makes $685,784 as Chief Scientific Officer at Opiant Pharmaceuticals Inc.
Sign up
Dr D OPNT stock SEC Form 4 insiders trading
Dr has made over 23 trades of the Opiant Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 480 units of OPNT stock worth $9,725 on 27 January 2023.
The largest trade he's ever made was exercising 10,000 units of Opiant Pharmaceuticals Inc stock on 2 January 2020 worth over $90,000. On average, Dr trades about 5,703 units every 57 days since 2018. As of 27 January 2023 he still owns at least 21,548 units of Opiant Pharmaceuticals Inc stock.
You can see the complete history of Dr Skolnick stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Phil Skolnick D.Sc. (hon), Ph.D. biography
Dr. Phil Skolnick D.Sc. (hon), Ph.D. is the Chief Scientific Officer at Opiant Pharmaceuticals Inc.
What is the salary of Dr D?
As the Chief Scientific Officer of Opiant Pharmaceuticals Inc, the total compensation of Dr D at Opiant Pharmaceuticals Inc is $685,784. There are 3 executives at Opiant Pharmaceuticals Inc getting paid more, with Roger Crystal having the highest compensation of $5,413,730.
How old is Dr D?
Dr D is 74, he's been the Chief Scientific Officer of Opiant Pharmaceuticals Inc since . There are 1 older and 8 younger executives at Opiant Pharmaceuticals Inc. The oldest executive at Opiant Pharmaceuticals Inc is Michael Sinclair, 77, who is the Executive Chairman of the Board.
What's Dr D's mailing address?
Phil's mailing address filed with the SEC is C/O OPIANT PHARMACEUTICALS, INC., 233 WILSHIRE BLVD., SUITE 400, SANTA MONICA, CA, 90401.
Insiders trading at Opiant Pharmaceuticals Inc
Over the last 21 years, insiders at Opiant Pharmaceuticals Inc have traded over $16,027,532 worth of Opiant Pharmaceuticals Inc stock and bought 199,545 units worth $2,080,156 . The most active insiders traders include Craig A Collard, Marc A Cohen, and Alain J Cohen. On average, Opiant Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $159,046. The most recent stock trade was executed by Roger Crystal on 27 January 2023, trading 1,358 units of OPNT stock currently worth $27,513.
What does Opiant Pharmaceuticals Inc do?
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
What does Opiant Pharmaceuticals Inc's logo look like?
Complete history of Dr Skolnick stock trades at Opiant Pharmaceuticals Inc
Opiant Pharmaceuticals Inc executives and stock owners
Opiant Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Roger Crystal,
President, Chief Executive Officer, Director -
Michael Sinclair,
Executive Chairman of the Board -
Dr. Roger Crystal,
Pres, CEO & Director -
Dr. Phil Skolnick D.Sc. (hon), Ph.D.,
Chief Scientific Officer -
David D. O'Toole,
Chief Financial Officer -
Michael Porter,
IR Contact Officer -
Richard Daly,
Independent Director -
Craig Collard,
Independent Director -
Thomas Thomas,
Director -
Gabrielle Silver,
Director -
Ann MacDougall,
Director -
Aziz Mottiwala,
Chief Commercial Officer -
Rahsaan Thompson,
General Counsel -
Phil Skolnick,
Chief Scientific Officer -
Arvind Agrawal,
Executive Vice President - Medical Affairs -
David O'Toole,
Chief Financial Officer -
Matthew R. Ruth,
Chief Commercial Officer -
Dr. Mark Heath Ellison Ph.D.,
Chief Devel. Officer -
Brian Gorman,
EVP Corp. Devel. & Gen. Counsel -
Ben Atkins,
VP of Communications & Investor Relations -
Matthew R. Ruth,
Chief Commercial Officer -
Ronald W Kaiser,
Director -
Melvin Iii Wesley,
Chief Financial Officer -
William F Stasior,
Director -
Steven G Finn,
Director -
Joseph W Kuhn,
VP & Chief Financial Officer -
Alain J Cohen,
President & Chief Tech Officer -
Marc A Cohen,
Chairman, CEO, Treas, & Sec -
Brian Gorman,
-
Mark Jason Heath Ellison,
Chief Development Officer -
Masuoka K. Lorianne,
Director